GeoVax Seeks Shareholder Nod for Warrant Exercise, Reverse Split

TL;DR

**GOVX is pushing a reverse split and massive warrant issuance – brace for dilution, but the Nasdaq listing might be saved.**

AI Summary

GeoVax Labs, Inc. (GOVX) is seeking stockholder approval for two critical proposals at a Special Meeting on November 26, 2025. The first proposal is to approve the issuance of up to 11,904,768 shares of common stock upon the exercise of September 2025 Warrants, issued to institutional investors in a private placement on September 30, 2025. These warrants have an exercise price of $0.63 per share and expire five years after stockholder approval. The second proposal is to amend the Company's Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-10 and not greater than 1-for-25, with the exact ratio and timing determined by the Board. As of the record date, September 30, 2025, there were 29,705,360 shares of common stock outstanding. The Board recommends a 'FOR' vote on both proposals, which are crucial for compliance with Nasdaq listing rules and potential stock price improvement.

Why It Matters

This DEF 14A filing is crucial for GeoVax investors as it outlines proposals directly impacting share structure and potential dilution. Approval of the 11,904,768 warrant shares could lead to significant dilution, while the reverse stock split, ranging from 1-for-10 to 1-for-25, aims to boost the per-share price, potentially to maintain Nasdaq listing compliance. For employees and customers, these financial maneuvers could stabilize the company's market position, but the dilution risk could weigh on investor confidence, affecting future capital raises. Competitively, a higher stock price post-split might make GOVX appear more robust compared to peers in the biotech sector.

Risk Assessment

Risk Level: high — The risk level is high due to the potential for significant dilution from the issuance of up to 11,904,768 shares upon warrant exercise, which represents a substantial portion of the 29,705,360 shares outstanding as of September 30, 2025. Additionally, while a reverse stock split aims to increase share price, it often signals underlying financial distress and does not guarantee long-term value appreciation, carrying a risk of further price decline post-split.

Analyst Insight

Investors should carefully evaluate the potential dilution from the 11,904,768 warrant shares and the implications of a reverse stock split on their holdings. Consider voting 'FOR' the proposals if you believe maintaining Nasdaq compliance and facilitating future capital raises are paramount for GeoVax's long-term viability, but be prepared for potential short-term volatility and dilution.

Key Numbers

• 11,904,768 — Shares of common stock (Maximum shares issuable upon exercise of September 2025 Warrants)
• $0.63 — Exercise price per share (Exercise price for the September 2025 Warrants)
• 1-for-10 — Minimum reverse stock split ratio (Proposed minimum ratio for the reverse stock split)
• 1-for-25 — Maximum reverse stock split ratio (Proposed maximum ratio for the reverse stock split)
• 29,705,360 — Shares of common stock outstanding (Total shares outstanding and entitled to vote as of September 30, 2025)
• 9,901,787 — Shares for quorum (Number of shares required for a quorum (one-third of outstanding shares))
• November 26, 2025 — Special Meeting Date (Date of the Special Meeting of Stockholders)
• September 30, 2025 — Record Date (Date for determining stockholders entitled to vote)

Key Players & Entities

• GeoVax Labs, Inc. (company) — Registrant
• Nasdaq Capital Market (regulator) — Listing rules authority
• Womble Bond Dickinson (US) LLP (company) — Location of Special Meeting
• Mark W. Reynolds (person) — Corporate Secretary of GeoVax Labs, Inc.
• Laurel Hill Advisory Group (company) — Proxy Solicitor for GeoVax Labs, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for filings
• Broadridge (company) — Vote Processing agent

FAQ

Risk Factors

• Nasdaq Listing Compliance [high — regulatory]: The company is seeking stockholder approval for two proposals critical for maintaining its Nasdaq listing. Failure to approve the issuance of shares upon warrant exercise or the reverse stock split could lead to delisting.
• Dilution from Warrant Exercise [medium — financial]: The exercise of up to 11,904,768 shares upon September 2025 Warrants at $0.63 per share represents a significant potential dilution to existing shareholders. This issuance is contingent on stockholder approval.
• Reverse Stock Split Impact [medium — financial]: The proposed reverse stock split, at a ratio between 1-for-10 and 1-for-25, aims to increase the stock price. However, reverse splits can sometimes be perceived negatively by the market and may not guarantee a sustained increase in share price.

Industry Context

GeoVax Labs operates in the biotechnology sector, focusing on vaccine development. This industry is characterized by high research and development costs, long development cycles, significant regulatory hurdles, and intense competition from established pharmaceutical companies and emerging biotech firms. Success often hinges on clinical trial outcomes and securing funding for ongoing research.

Regulatory Implications

The company's primary regulatory concern highlighted in this filing is compliance with Nasdaq listing rules. The proposed actions, including the warrant exercise and reverse stock split, are directly aimed at meeting these requirements to avoid delisting.

What Investors Should Do

1. Vote 'FOR' the September 2025 Warrant Exercise Proposal to approve the issuance of up to 11,904,768 shares upon warrant exercise, which is necessary for Nasdaq compliance.
2. Vote 'FOR' the reverse stock split proposal to approve an amendment to the Certificate of Incorporation, enabling a split ratio between 1-for-10 and 1-for-25, also crucial for Nasdaq compliance and potential stock price improvement.
3. Review the proxy materials carefully to understand the potential dilution from warrant exercise and the implications of a reverse stock split before casting your vote.
4. Ensure your vote is cast by November 25, 2025, if voting by internet or telephone, or submit your proxy card promptly to ensure it is received by the tabulator.

Key Dates

• 2025-09-30: Private Placement of September 2025 Warrants — This date established the record for determining stockholders entitled to vote at the Special Meeting and is the date the warrants were issued.
• 2025-10-14: Mailing of Proxy Materials — This is the date stockholders began receiving the official proxy statement and notice of the Special Meeting.
• 2025-11-25: Internet and Telephone Voting Deadline — This is the deadline for stockholders to cast their votes online or by phone before the Special Meeting.
• 2025-11-26: Special Meeting of Stockholders — The date for the stockholder vote on the two critical proposals: warrant exercise approval and reverse stock split approval.

Glossary

DEF 14A

A filing with the SEC that provides definitive proxy material for the solicitation of proxies from shareholders. (This document outlines the proposals to be voted on at the Special Meeting and provides background information for shareholders.)

September 2025 Warrants

Warrants issued on September 30, 2025, to institutional investors, allowing them to purchase up to 11,904,768 shares of common stock at $0.63 per share. (Stockholder approval is required for the issuance of shares upon the exercise of these warrants, which is a key agenda item for the Special Meeting.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (GeoVax is proposing a reverse stock split to potentially increase its stock price and comply with Nasdaq listing requirements.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or receive other distributions. (September 30, 2025, is the record date for determining which stockholders are entitled to vote at the Special Meeting.)

Quorum

The minimum number of shareholders or shares required to be present at a meeting for business to be legally transacted. (One-third of the outstanding shares (9,901,787 shares as of September 30, 2025) must be represented for a quorum at the Special Meeting.)

Broker Non-Vote

Occurs when a broker holding shares on behalf of a client does not vote on a particular proposal because the client has not provided instructions and the broker lacks discretionary authority to vote. (Broker non-votes can impact the outcome of proposals if they reduce the number of votes cast, although they are counted for quorum purposes.)

Year-Over-Year Comparison

This DEF 14A filing focuses on an upcoming Special Meeting and proposals critical for Nasdaq compliance, rather than a comparison of financial performance against a prior year's annual report. Key metrics such as revenue, net income, and margins are not detailed in this specific proxy statement, making a direct year-over-year comparison of financial performance impossible from this document alone.

Key Financial Figures

• $0.63 — arrants have an exercise price equal to $0.63 per share and expire five years after S
• $10 — pay liquidated damages in the amount of $10 per trading day foreach $1,000 of the s
• $1,000 — e amount of $10 per trading day foreach $1,000 of the shares of common stock exercised
• $20 — rcised but not delivered (and rising to $20 per trading day beginning the third tra
• $0 — use such exercise price to be less than $0.63, as adjusted for any stock dividend,

Filing Documents

• govx20251010_def14a.htm (DEF 14A) — 185KB
• reynoldssig.jpg (GRAPHIC) — 5KB
• 0001437749-25-030934.txt ( ) — 194KB

From the Filing

DEF 14A 1 govx20251010_def14a.htm FORM DEF 14A govx20251010_def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a- 6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 GEOVAX LABS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. GEOVAX LABS, INC. 1900 Lake Park Drive Suite 380 Smyrna, Georgia 30080 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS Dear Stockholder: You are hereby notified that a Special Meeting of Stockholders ("Special Meeting") of GeoVax Labs, Inc. ("GeoVax" or the "Company") will be held on November 26, 2025, at 8:30 a.m. local time, at the offices of Womble Bond Dickinson (US) LLP, 1331 Spring Street, NW, Suite 1400, Atlanta, Georgia 30309, for the following purposes: 1. To approve, pursuant to Nasdaq listing rules, the issuance of up to 11,904,768 shares of our common stock upon the exercise of common stock purchase warrants (the "September 2025 Warrants") issued to certain institutional investors in connection with the private placement offering which occurred on September 30, 2025 (the "September 2025 Warrant Exercise Proposal"); and 2. To approve an amendment to the Company's Certificate of Incorporation to effect a reverse split of our issued and outstanding common stock at a ratio of not less than 1-for-10 and not greater than 1-for-25, such ratio to be determined by our Board, the implementation and timing of which shall be subject to the discretion of our Board. Holders of our common stock owning such shares of record at the close of business on September 30, 2025 are entitled to attend and vote at the Special Meeting and any continuation or adjournment thereof. The enclosed Proxy Statement more fully describes the details of the business to be conducted at the Special Meeting. The Company does not contemplate discussing any other business at the meeting. Your vote is very important. Please vote whether or not you plan to attend the Special Meeting. Your promptness in voting will assist us in ensuring that a quorum is present or represented. The Notice of Internet Availability of Proxy Materials contains instructions on how to vote online or by telephone. If you have received a paper copy of our proxy materials, please mark, date, and sign and return the enclosed proxy card in the accompanying reply envelope to ensure receipt by our tabulator. You may also vote on-line or by phone by following the instructions contained in the accompanying Proxy Statement. You may attend the Special Meeting and vote your shares in person if you wish. If you have any questions or need assistance voting your shares, please contact our Proxy Solicitor: Laurel Hill Advisory Group Banks and Brokers Call (516) 933-3100 All Others Call Toll-Free (888) 742-1305 By Order of the Board of Directors Mark W. Reynolds Corporate Secretary October 14, 2025 Smyrna, Georgia TABLE OF CONTENTS Page PROXY STATEMENT 1 QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING 1 PROPOSAL 1 -- APPROVAL OF THE SEPTEMBER 2025 WARRANT EXERCISE PROPOSAL 4 PROPOSAL 2 -- AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT 9 ANNEX A -- CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF GEOVAX LABS, INC. A-1 GEOVAX LABS, INC. 1900 Lake Park Drive Suite 380 Smyrna, Georgia 30080 PROXY STATEMENT For The SPECIAL MEETING OF STOCKHOLDERS To Be Held November 26, 2025 This Proxy Statement is furnished in connection with the solicitation of your proxy on behalf of the Board of Directors (the "Board") by GeoVax Labs, Inc., a Delaware corporation ("GeoVax" or the "Company"), for use at a Special Meeting of Stockholders (the "Special Meeting") to be held at the offices of Womble Bond Dickinson (US) LLP, 1331 Spring Street, NW, Suite 1400, Atlanta, Georgia 30309, on November 26, 2025, at 8:30 a.m. local time and at any adjournment or postponement thereof. Our Board of Directors has fixed the close of business on September 30, 2025 as the record date ("Record Date") for determining GeoVax stockholders entitled to notice of and to vote at the Special Meeting and at any adjournment or postponement thereof. Important Notice Regarding the Internet Availability of Proxy Materials for the Special Meeting. On or about October 14, 2025, the Company started mailing to its

View Full Filing

View this DEF 14A filing on SEC EDGAR